371 related articles for article (PubMed ID: 11156242)
1. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
[TBL] [Abstract][Full Text] [Related]
2. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF
Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766
[TBL] [Abstract][Full Text] [Related]
3. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
[TBL] [Abstract][Full Text] [Related]
4. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
5. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
Fay JW; Palucka AK; Paczesny S; Dhodapkar M; Johnston DA; Burkeholder S; Ueno H; Banchereau J
Cancer Immunol Immunother; 2006 Oct; 55(10):1209-18. PubMed ID: 16331519
[TBL] [Abstract][Full Text] [Related]
7. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
10. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
11. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
12. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
[TBL] [Abstract][Full Text] [Related]
14. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
15. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
16. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
Lee PP; Yee C; Savage PA; Fong L; Brockstedt D; Weber JS; Johnson D; Swetter S; Thompson J; Greenberg PD; Roederer M; Davis MM
Nat Med; 1999 Jun; 5(6):677-85. PubMed ID: 10371507
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
20. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
